Mutual Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$62.8M Buy
68,302
+2,493
+4% +$2.53M 1.35% 9
2025
Q4
$70.7M Buy
65,809
+55
+0.1% +$52.6K 1.52% 8
2025
Q3
$54M Buy
65,754
+1,963
+3% +$1.46M 1.19% 10
2025
Q2
$51.8M Buy
63,791
+328
+0.5% +$255K 1.29% 9
2025
Q1
$56.1M Buy
63,463
+19
+0% +$15.8K 1.61% 8
2024
Q4
$48.1M Buy
63,444
+1,881
+3% +$1.56M 1.39% 8
2024
Q3
$54.9M Buy
61,563
+53
+0.1% +$47.6K 1.6% 7
2024
Q2
$49.7M Sell
61,510
-1,088
-2% -$870K 1.5% 7
2024
Q1
$48.7M Buy
62,598
+50,197
+405% +$35.7M 1.56% 7
2023
Q4
$7.23M Buy
12,401
+2,098
+20% +$1.22M 0.25% 74
2023
Q3
$5.53M Sell
10,303
-2,418
-19% -$1.25M 0.22% 89
2023
Q2
$5.97M Buy
12,721
+1,801
+16% +$755K 0.23% 90
2023
Q1
$3.75M Buy
10,920
+1,081
+11% +$365K 0.15% 138
2022
Q4
$3.6M Buy
9,839
+368
+4% +$130K 0.16% 133
2022
Q3
$3.06M Sell
9,471
-315
-3% -$99.8K 0.16% 129
2022
Q2
$3.17M Sell
9,786
-524
-5% -$157K 0.21% 109
2022
Q1
$2.95M Buy
10,310
+21
+0.2% +$5.41K 0.17% 145
2021
Q4
$2.84M Sell
10,289
-505
-5% -$128K 0.15% 164
2021
Q3
$2.49M Buy
10,794
+851
+9% +$210K 0.15% 174
2021
Q2
$2.28M Buy
9,943
+55
+0.6% +$11K 0.14% 188
2021
Q1
$1.85M Buy
9,888
+883
+10% +$173K 0.13% 201
2020
Q4
$1.52M Sell
9,005
-1,155
-11% -$172K 0.11% 216
2020
Q3
$1.5M Sell
10,160
-203
-2% -$31.4K 0.13% 180
2020
Q2
$1.7M Buy
10,363
+597
+6% +$91.6K 0.17% 145
2020
Q1
$1.35M Buy
9,766
+401
+4% +$55.1K 0.18% 144
2019
Q4
$1.23M Buy
9,365
+279
+3% +$32.3K 0.13% 190
2019
Q3
$1.02M Buy
9,086
+168
+2% +$18.7K 0.13% 189
2019
Q2
$988K Sell
8,918
-25
-0.3% -$2.94K 0.13% 201
2019
Q1
$1.16M Sell
8,943
-152
-2% -$18.5K 0.17% 143
2018
Q4
$1.05M Buy
9,095
+57
+0.6% +$6.37K 0.21% 122
2018
Q3
$970K Buy
9,038
+2,438
+37% +$244K 0.15% 173
2018
Q2
$563K Buy
6,600
+512
+8% +$42.1K 0.13% 220
2018
Q1
$471K Buy
6,088
+620
+11% +$49.9K 0.12% 244
2017
Q4
$462K Buy
+5,468
New +$465K 0.17% 163

Other funds holding LLY

Mutual Advisors's LLY Position: Q1 2026 in Review

Mutual Advisors increased its Eli Lilly (LLY) stake by 3.8% in Q1 2026, buying an estimated $2.53M and bringing the position to 68,302 shares worth $62.8M. The position accounts for 1.35% of the portfolio, ranked #9.

Mutual Advisors first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. The position peaked at $70.7M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Mutual Advisors held 68,302 shares of Eli Lilly worth $62.8M as of Q1 2026.
  • Mutual Advisors bought 2,493 Eli Lilly shares in Q1 2026, an estimated $2.53M.
  • Eli Lilly made up 1.35% of Mutual Advisors's portfolio in Q1 2026, its #9 holding.
  • Mutual Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
  • Mutual Advisors's Eli Lilly position peaked at $70.7M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Mutual Advisors's 13F filing for Q1 2026, filed 4 May 2026.